Use of proton-pump inhibitors among adults: A Danish nationwide drug utilization study

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 5, 2016, Pages 671-678

  Pottegård, Anton ^a   Broe, Anne ^a   Hallas, Jesper ^a   De Muckadell, Ove B Schaffalitzky ^b   Lassen, Annmarie T ^b   Lødrup, Anders B ^c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

general population; incidence; prescription registry; prevalence; proton pump inhibitor; ulcerogenic drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DANE (PEOPLE); DESCRIPTIVE RESEARCH; DRUG UTILIZATION; FEMALE; HELICOBACTER INFECTION; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; VERY ELDERLY;

EID: 84981212374     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16650156     Document Type: Article

References (35)

1. Abraham N., Hlatky M., Antman E., Bhatt D., Bjorkman D., Clark C., et al. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 56: 2051-2066.
2. Ahrens D., Behrens G., Himmel W., Kochen M., Chenot J., (2012) Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract 66: 767-773.
3. Batuwitage B., Kingham J., Morgan N., Bartlett R., (2007) Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 83: 66-68.
4. Bhatt D., Scheiman J., Abraham N., Antman E., Chan F., Furberg C., et al. (2008) ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52: 1502-1517.
5. Björnsson E., Abrahamsson H., Simrén M., Mattsson N., Jensen C., Agerforz P., et al. (2006) Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharm Therap 24: 945-954.
6. Dall M., Schaffalitzky de Muckadell O., Lassen A., Hansen J., Hallas J., (2009) An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 7: 1314-1321.
7. Danish National Institute for Health Data and Disease Control, Drug Consumption in Norway, and The Swedish National Board of Health and Welfare. Total sale of PPI and H2RA in Denmark, Norway and Sweden. 2013. Available at: www.medstat.dk, www.legemiddelforbruk.no, www.socialstyrelsen.se (. accessed 10 May 2016).
8. El-Serag H., Sweet S., Winchester C., Dent J., (2014) Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 63: 871-880.
9. Gómez-Outes A., Terleira-Fernández A., Calvo-Rojas G., Suárez-Gea M., Vargas-Castrillón E., (2013) Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis 2013: 640723.
10. Haastrup P., Paulsen M., Zwisler J., Begtrup L., Hansen J., Rasmussen S., et al. (2014) Rapidly increasing prescribing of proton pump inhibitors in primary care despite interventions: a nationwide observational study. Eur J Gen Pract 20: 290-293.
11. Hungin A., Hill C., Molloy-Bland M., Raghunath A., (2012) Systematic review: Patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 10: 109-116.
12. Hungin A., Rubin G., O'Flanagan H., (1999) Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 49: 451-453.
13. Jacobson B., Ferris T., Shea T., Mahlis E., Lee T., Wang T., (2003) Who is using chronic acid suppression therapy and why? Am J Gastroenterol 98: 51-58.
14. Kildemoes H., Sørensen H., Hallas J., (2011) The Danish National Prescription Registry. Scand J Public Health 39: 38-41.
15. Ko Y., Tang J., Sanagapalli S., Kim B., Leong R., (2016) Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms. Expert Opin Drug Saf 15: 53-63.
16. Lassen A., Hallas J., Schaffalitzky De Muckadell O., (2004) Use of anti-secretory medication: a population-based cohort study. Aliment pharm therap 20: 577-583.
17. Lødrup A., Reimer C., Bytzer P., (2013) Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol 48: 515-522.
18. Lødrup A., Reimer C., Bytzer P., (2014) Use of antacids, alginates and proton pump inhibitors: a survey of the general Danish population using an internet panel. Scand J Gastroenterol 49: 1044-1050.
19. Narum S., Westergren T., Klemp M., (2014) Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ open 4: e004587.
20. National Institute for Health and Care Excellence. (2014) Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. NICE guideline CG184.
21. Pedersen C., (2011) The Danish Civil Registration System. Scand J Public Health 39: 22-25.
22. Reimer C., (2013) Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 27: 443-454.
23. Reimer C., Bytzer P., (2009) A population-based survey to assess troublesome symptoms in gastroesophageal reflux disease. Scand J Gastroenterol 44: 394-400.
24. Reimer C., Bytzer P., (2010) Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. Eur J Gastroenterol Hepatol 22: 1182-1188.
25. Ronkainen J., Aro P., Storskrubb T., Johansson S., Lind T., Bolling-Sternevald E., et al. (2005a) High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 40: 275-285.
26. Ronkainen J., Aro P., Storskrubb T., Johansson S., Lind T., Bolling-Sternevald E., et al. (2005b) Prevalence of Barrett's Esophagus in the general population: an endoscopic study. Gastroenterol 129: 1825-1831.
27. Statens Serum Institut (2015) Statens Serum Institut. Medstat.dk. Available at: www.medstat.dk/en (. accessed 10 May 2016).
28. European branch of the Special Interest Group for Drug Utilization Research (SIGDUR). Cross-National comparison of drug utilisation activities. Bremen, Germany: University of Bremen, Department of Pharmeceutical Epidemiology and Public Health.
29. Thygesen L., Daasnes C., Thaulow I., Brønnum-Hansen H., (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 39: 12-16.
30. Valkhoff V., van Soest E., Sturkenboom M., Kuipers E., (2010) Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharm Therap 31: 1218-1228.
31. Van Soest E., Siersema P., Dieleman J., Sturkenboom M., Kuipers E., (2006) Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharm Therap 24: 377-385.
32. Van Soest E., Valkhoff V., Mazzaglia G., Schade R., Molokhia M., Goldstein J., et al. (2011) Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 60: 1650-1659.
33. Wermeling M., Himmel W., Behrens G., Ahrens D., (2014) Why do GPs continue inappropriate hospital prescriptions of proton pump inhibitors? A qualitative study. Eur J Gen Pract 20: 174-180.
34. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2015. Oslo, 2014.
35. Zwisler J., Jarbøl D., Lassen A., Kragstrup J., Thorsgaard N., Schaffalitzky de Muckadell O., (2015) Placebo-controlled discontinuation of long-term acid-suppressant therapy: a randomised trial in general practice. Int J Family Med 2015: 175436.